ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

NCT06463327 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: TCB008

Sponsor

TC Biopharm